SAB Biotherapeutics Inc. (SABS)

NASDAQ: SABS · IEX Real-Time Price · USD
1.92
-0.12 (-5.88%)
May 20, 2022 4:30 PM EDT - Market closed

Income Statement (Quarterly)

Millions USD. Fiscal year is Jan - Dec.
Quarter Ended2022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-30
Revenue
11.811.0614.68-16.9325.7617.47
Revenue Growth (YoY)
-30.27%-57.06%-15.96%----
Gross Profit
11.811.0614.68-16.9325.7617.47
Selling, General & Admin
5.197.753.6-3.331.862.5
Research & Development
13.3210.6515.07-12.7815.315.02
Operating Expenses
18.5118.418.67-16.1117.177.52
Operating Income
-6.71-7.34-3.99-0.818.589.95
Interest Expense / Income
0.070.070.08-0.080.140.03
Other Expense / Income
-7.864.14-00-0.67-0.01-0.01
Pretax Income
1.08-11.55-4.0601.418.449.93
Income Tax
0.0900-000
Net Income
0.99-11.55-4.06-1.418.449.93
Net Income Common
0.99-11.55-4.06-1.418.449.93
Net Income Growth
-30.07%------
Shares Outstanding (Basic)
43273535262535
Shares Outstanding (Diluted)
462735-282760
Shares Change
63.21%1.21%-41.21%----
EPS (Basic)
0.02-0.47-0.12-0.050.570.19
EPS (Diluted)
0.02-0.47-0.12-0.050.540.17
EPS Growth
-60.00%------
Free Cash Flow Per Share
-0.27-0.200.02-0.29-0.03-0.01
Gross Margin
100.00%100.00%100.00%-100.00%100.00%100.00%
Operating Margin
-56.83%-66.41%-27.16%-4.81%33.32%56.97%
Profit Margin
8.35%-104.46%-27.66%-8.33%32.79%56.82%
Free Cash Flow Margin
-98.06%-49.45%3.88%-44.68%-3.18%-2.84%
Effective Tax Rate
8.56%0.00%0.00%-0.00%0.00%0.00%
EBITDA
1.83-10.82-3.57-1.768.7910.1
EBITDA Margin
15.48%-97.88%-24.30%-10.41%34.12%57.81%
EBIT
1.15-11.49-3.98-1.498.599.96
EBIT Margin
9.74%-103.86%-27.13%-8.77%33.34%57.01%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).